Thyroid Eye Disease clinical trials at UCSF
1 research study open to eligible people
Thyroid eye disease affects the eyes and can cause pain, swelling, and vision loss. UCSF is conducting a clinical trial to study a new drug called VRDN-001 that could help treat this disease. The study is looking for healthy volunteers and people with thyroid eye disease to test the safety and effectiveness of the drug.
A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
open to eligible people ages 18 years and up
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.
San Francisco, California and other locations